[A21-146] Nivolumab (gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction or the oesophagus) - Benefit assessment according to §35a Social Code Book V
Last updated 19.05.2022
Commission awarded on 19.11.2021 by the Federal Joint Committee (G-BA).
First-line treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic gastric (stomach), gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express Programmed Cell Death-Ligand 1 (PD-L1, Combined Positive Score [CPS] ≥ 5)
- Adenocarcinoma of the oesophagus: added benefit not proven.
- Adenocarcinoma of the stomach or of the gastro-oesophageal junction: hint of non-quantifiable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.